ALK and neoplasm: Continued treatment of ALK-positive NSCLC with crizotinib despite development of renal cysts was associated with ongoing tumor control, since RECIST-defined responses were maintained for a median of 14.0 months from treatment initiation in the 14 patients with objective responses.